$41.57 Billion Forecast for Acquired Immunodeficiency Syndrome (AIDS) Market by 2029, Backed by Demand and Innovation
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Estimated Market Size of the Acquired Immunodeficiency Syndrome (AIDS) Market In 2029?
The market size for acquired immunodeficiency syndrome (AIDS) has seen a robust growth in the past years, expanding from $32.09 billion in 2024 to an expected $33.85 billion in 2025. This equates to a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this ascend during the historic period can be traced back to the elevated rates of HIV infections, the increase in government fund allocations for HIV therapy, the proliferation of global awareness initiatives, the enhancement in diagnostic competency, and the rising backing from non-governmental associations.
Growth in the acquired immunodeficiency syndrome (AIDS) market is anticipated to be robust in the coming years, with its worth expected to skyrocket to $41.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.3%. This increased growth during the forecast period can be credited to factors such as the heightened demand for long-acting injectable therapies, the rising use of pre-exposure prophylaxis (PrEP), an escalation in the funding for HIV cure research, the surge in telemedicine services for managing HIV, the escalating emphasis on personalized medicine, as well as the growing consciousness about early detection of HIV. The forecast period will likely see trends such as a shift towards single-tablet regimens, a heightened inclination towards injectable and implantable HIV treatments, a ballooning demand for digital health solutions for HIV management, a growing fascination with functional HIV cure tactics, and a burgeoning role of artificial intelligence in pharmaceutical discovery.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
What Are the Core Growth Drivers Propelling the Acquired Immunodeficiency Syndrome (AIDS) Market Forward?
The growth of the acquired immunodeficiency syndrome (AIDS) market is anticipated to be driven by the rising incidence rates of HIV infections. HIV or human immunodeficiency virus infections are diseases where the HIV virus attacks the immune system, compromising the body’s capacity to fend off diseases and infections. Unprotected sexual contact with an infected person, needle or syringe sharing, transfusing contaminated blood products, having many sexual partners, and a compromised immune system or existent sexually transmitted infections contribute to the rise in HIV rates. AIDS management aids those with HIV infections through encouraging early detection, broadening the reach of effective antiretroviral treatments, improving prevention approaches, and fortifying healthcare infrastructures that can aid in better containment of the virus. For instance, data from the European Centre for Disease Prevention and Control (ECDC), a Sweden-based agency of the European Union, reported in November 2024, disclosed that there were 112,883 HIV diagnoses logged in 2023 in 47 out of 53 nations in the region, with 24,731 instances noted in the European Union/European Economic Area (EU/EEA). The total crude rate of HIV diagnoses came to 12.7 per 100,000 people, denoting a 2.4% surge compared to the 12.4 per 100,000 rates noted in 2022. Consequently, the rising number of HIV infections is spurring the growth of the acquired immunodeficiency syndrome (AIDS) market.
What Segment Types Define the Acquired Immunodeficiency Syndrome (AIDS) Market Structure?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Acquired Immunodeficiency Syndrome (AIDS) Market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theAcquired Immunodeficiency Syndrome (AIDS) Industry Evolution?
In the acquired immunodeficiency syndrome (AIDS) market, key players are turning their focus to the development of innovative treatment approaches such as long-acting injectables. These new therapies are designed to enhance patient compliance, minimize dosing frequency, and provide a more practical solution than conventional daily oral antiretroviral treatments. Long-acting injectables slowly release their active ingredients over time through injections, effectively reducing the need for daily oral medications. For example, GSK plc., a pharmaceutical firm based in the UK, received approval from the European Commission in January 2025 for a long-acting injectable treatment known as Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment, which is approved for HIV-positive adolescents aged 12 years and older, is typically administered through intramuscular injection every one to two months based on the specific treatment program. The prolonged efficacy of these injections can potentially increase compliance rates among teenagers who find it difficult to adhere to daily pill schedules.
View the full report here:
What Is the Definition of the Acquired Immunodeficiency Syndrome (AIDS) Market?
Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by destroying CD4 T cells, leaving the body vulnerable to opportunistic infections, severe illnesses, and certain cancers in the absence of effective antiretroviral treatment. It is managed by a combination of antiretroviral therapy (ART), regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to improve patient outcomes and quality of life.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
